A Phase 2 interventional study of AZD1722 (in-patient) and Placebo (in-patient) in End Stage Renal Disease, Chronic Kidney Disease Stage 5 and ESRD, sponsored by Ardelyx. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-10.
Sponsored by Ardelyx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 235th largest by enrollment of the 638 interventional ones that give a count, is one of 38 that started in 2013, is one of 87 in phase 2, and was the 307th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:
United Therapeutics · Sites in United States
Ages 40–70
Xeno Holdings (US), LLC dba ChoironeX · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 18+
Basilea Pharmaceutica · Sites in United States
Ages 18–80 · Healthy volunteers
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
765 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 119 · Phase 2 130 · Phase 3 89 · Phase 4 61
First in 1995; this study’s year is marked. 38 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 48 across the 638 interventional studies, 100 across the 121 observational. Of the 610 that completed or were terminated, 267 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 765 have an industry lead sponsor. The 10 most frequent:
Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Ardelyx has 3 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
43 of the studies in Kidney Failure, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT05931276Phase 3VA Office of Research and DevelopmentCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes | 2026-12-31 |
| NCT03321656Phase 3Roberto GedalyImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile | 2027-03-31 |
| NCT05908084Phase 3Humacyte, Inc.To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
Add all 43 to your calendar (.ics) → With an account.
Among the 765 studies in Kidney Failure, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of the study drug in male and female patients with end-stage renal disease on hemodialysis. The study consists of a 2 week treatment-free run-in period where entry criteria are verified, a 4-week treatment period, of which the first week of treatment will be performed as an in-patient study in a clinical pharmacology unit (CPU) and the remaining three weeks of treatment will performed as an out-patient study, and a 2-week treatment-free follow-up period.
Safety assessments will be performed at regular intervals and will include clinical and vital signs, clinical laboratory evaluations, ECGs, and AE monitoring. Pharmacodynamic assessments will include, but are not limited to, interdialytic weight gain (IDWG), blood pressure, and stool sodium excretion. Pharmacokinetic assessments will include blood sampling for measurement of study drug plasma concentrations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tenapanor administered in a clinical pharmacology unit
Drug: AZD1722 (in-patient)
Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit
Drug: Placebo (in-patient)
Tenapanor
Drug: AZD1722 (out-patient)
Placebo
Drug: Placebo
doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting
Also known as: RDX5791, Tenapanor
Placebo, size and color matched to experimental drug administered in a CPU
doses between 5 and 45 mg BID
Also known as: Tenapanor
Placebo, size and color matched to experimental drug
Change in Mean Weekly Interdialytic Weight Gain (IDWG)
Patients are weighed pre dialysis prior to their first dialysis of the week. This measure looks at the change in pre-dialysis weight over time
Time frame: Run-in period (Weeks -2 and -1) versus Week 4 (end of treatment)
Stool Sodium Content
The amount of sodium in a days worth of stool output
Time frame: Days 1 through 7
| Milestone | AZD1722- in Patient | Placebo- in Patient | AZD1722 Out-patient | Placebo Out-patient |
|---|---|---|---|---|
| Started | 8 | 8 | 37 | 35 |
| Completed | 8 | 8 | 31 | 33 |
| Not completed | 0 | 0 | 6 | 2 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Relocation | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 2 |
Patients are weighed pre dialysis prior to their first dialysis of the week. This measure looks at the change in pre-dialysis weight over time
| kilograms | AZD1722 Out-patient | Placebo Out-patient |
|---|---|---|
| Change in Mean Weekly Interdialytic Weight Gain (IDWG) | -0.26 ± 0.939 | -0.23 ± 0.871 |
The amount of sodium in a days worth of stool output
| mEq/day | AZD1722- in Patient | Placebo- in Patient |
|---|---|---|
| Stool Sodium Content | 36.62 ± 21.809 | 2.82 ± 2.655 |
Collected over one month. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD1722- in Patient | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Placebo- in Patient | 0/8 (0%) | 3/8 (37.5%) | 2/8 (25%) |
| AZD1722 Out-patient | 0/37 (0%) | 2/37 (5.4%) | 3/37 (8.1%) |
| Placebo Out-patient | 0/35 (0%) | 1/35 (2.9%) | 21/35 (60%) |
| Event | AZD1722- in Patient | Placebo- in Patient | AZD1722 Out-patient | Placebo Out-patient |
|---|---|---|---|---|
| SyncopeCardiac disorders | 0/8 | 1/8 | 1/37 | 0/35 |
| acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/8 | 1/8 | 0/37 | 0/35 |
| local swellingNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 1/8 | 0/37 | 0/35 |
| pneumoniaRespiratory, thoracic and mediastinal disorders | 0/8 | 0/8 | 0/37 | 1/35 |
| Urinary Tract InfectionRenal and urinary disorders | 0/8 | 0/8 | 1/37 | 0/35 |
| Event | AZD1722- in Patient | Placebo- in Patient | AZD1722 Out-patient | Placebo Out-patient |
|---|---|---|---|---|
| diarrheaGastrointestinal disorders | 6/8 | 2/8 | 3/37 | 21/35 |
| Age, Continuous(years) | AZD1722- in Patient | Placebo- in Patient | AZD1722 Out-patient | Placebo Out-patient | Total |
|---|---|---|---|---|---|
| Mean | 47.9 ± 8.3 | 54.4 ± 6.5 | 51.5 ± 11.5 | 49.3 ± 11.8 | 50.6 ± 11.6 |
| Sex: Female, Male(Participants) | AZD1722- in Patient | Placebo- in Patient | AZD1722 Out-patient | Placebo Out-patient | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 13 | 15 | 33 |
| Male | 6 | 5 | 24 | 20 | 55 |
| Ethnicity (NIH/OMB)(Participants) | AZD1722- in Patient | Placebo- in Patient | AZD1722 Out-patient | Placebo Out-patient | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 13 | 10 | 24 |
| Not Hispanic or Latino | 7 | 8 | 24 | 25 | 64 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AZD1722- in Patient | Placebo- in Patient | AZD1722 Out-patient | Placebo Out-patient | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 6 | 14 | 19 | 45 |
| White | 2 | 2 | 18 | 16 | 38 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Height(centimeters) | AZD1722- in Patient | Placebo- in Patient | AZD1722 Out-patient | Placebo Out-patient | Total |
|---|---|---|---|---|---|
| Mean | 172.89 ± 9.31 | 172.05 ± 16.48 | 170.23 ± 10.80 | 170.20 ± 10.39 | 170.63 ± 10.84 |
The record gives a start of Jan 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2020, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenapanor